Lauren Elizabeth Damon, M.D. for UC Davis Health

Lauren Elizabeth Damon, M.D.

Lauren Elizabeth Damon, M.D.

Associate Physician

Lauren Elizabeth Damon is not currently accepting new patients. For assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Reviews

Specialties

Hospitalist

Department

Internal Medicine

Locations and Contact

UC Davis Medical Center

UC Davis Medical Center
2315 Stockton Blvd.
Sacramento, CA 95817

Get Directions

Clinical Interests

Dr. Damon is a hospitalist dedicated to providing high quality, patient-centered care for adults in the hospital and to providing medical education to student and resident learners

Division

Hospital Medicine

Undergraduate School

B.S., Molecular and Cellular Biology, Johns Hopkins University, Baltimore MD 2013

Medical School

M.D., UC San Francisco, San Francisco CA 2017

Internship

Internal Medicine, UC Davis Medical Center, Sacramento CA 2017-2018

Residency

Internal Medicine, UC Davis Medical Center, Sacramento CA 2018-2020

Diamond Doc Award (Winter and Spring), 2022

Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun;5(6):668-79. doi:10.1158/2159-8290.CD-15-0060. Epub 2015 Apr 6. PMID:25847190.

Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. doi:10.1073/pnas.1320661111. Epub 2014 Mar 12. PMID:24623852.

Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18;121(16):3165-71. doi:10.1182/blood-2012-07-442871. Epub 2013 Feb 21. PMID:23430109.

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 Apr 15;485(7397):260-3. doi:10.1038/nature11016. PMID:22504184.

Damon LE, Damon LE. Mobilization of hematopoietic stem cells into the peripheral blood. Expert Rev Hematol. 2009 Dec;2(6):717-33. doi:10.1586/ehm.09.54. PMID:21082960.

Damon L, Damon LE, Gaensler K, Kaplan L, Martin T 3rd, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008 Nov;42(10):649-57. doi:10.1038/bmt.2008.236. Epub 2008 Aug 4. PMID:18679366.